New insider activity at Incyte ( (INCY) ) has taken place on February 23, 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
In a notable insider move at Incyte, President of R&D Pablo Cagnoni has sold 18,668 shares of company stock, with the transaction totaling $1,883,787. This sizable sale by a key executive may draw attention from investors tracking insider activity and leadership confidence at the biopharmaceutical firm.
Recent Updates on INCY stock
Incyte’s shares reacted to news that a Phase 1b/2a basket trial combining tafasitamab and parsaclisib in relapsed or refractory non‑Hodgkin lymphoma and chronic lymphocytic leukemia has been terminated. The halt removes a prospective growth driver from its hematology pipeline, sharpening focus on clinical execution risk and shifting investor expectations toward the company’s other late‑stage assets and competing CD19 or PI3K programs in the market.
Spark’s Take on INCY Stock
According to Spark, TipRanks’ AI Analyst, INCY is a Outperform.
Score is driven primarily by strong financial strength (low leverage, high margins, and a major 2025 profitability/cash rebound) and supportive technical momentum (price above major moving averages with positive MACD). The rating is moderated by profit/cash-flow volatility over time, reasonable-but-not-bargain valuation (P/E ~18.3 with no dividend), and earnings-call execution risks (PN setback, higher R&D, and the need to broaden growth beyond Jakafi).
To see Spark’s full report on INCY stock, click here.
More about Incyte
YTD Price Performance: 3.00%
Average Trading Volume: 2,039,656
Technical Sentiment Signal: Buy
Current Market Cap: $20.5B